四环医药(00460.HK) 公布，旗下非全资附属轩竹生物研发的创新药“吡洛西利”取得重大科研突破，其联合氟维司群治疗HR+╱HER2-晚期乳腺癌临床III期研究期中分析结果，已正式刊登于顶级期刊Nature子刊《Nature Communications》。
公告指，吡洛西利联合氟维司群疗效显著。尤其是内分泌原发耐药、单纯骨转移、肝转移患者风险降低明显，并能使肿瘤缩小，缓解症状，带来生存获益。在本次研究中，吡洛西利面对人群更复杂、疾病更难治的挑战，依然获得突出生存数据。(js/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-09 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.